PharmaCyte Biotech Files 8-K/A Amendment
Ticker: PMCB · Form: 8-K/A · Filed: Nov 18, 2025 · CIK: 1157075
| Field | Detail |
|---|---|
| Company | Pharmacyte Biotech, Inc. (PMCB) |
| Form Type | 8-K/A |
| Filed Date | Nov 18, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $0.001, $3,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
PharmaCyte Biotech filed an amendment to its 8-K, updating financial statements and exhibits.
AI Summary
PharmaCyte Biotech, Inc. filed an amendment (8-K/A) on November 18, 2025, to a previous report dated September 2, 2025. This amendment pertains to financial statements and exhibits. The company, formerly known as NuVilex, Inc., is incorporated in Nevada and operates in the biological products sector.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information, which could be material for investors assessing the company's financial status or disclosures.
Risk Assessment
Risk Level: low — This is a routine amendment to a previous filing, not indicating new material events or significant financial changes.
Key Players & Entities
- PharmaCyte Biotech, Inc. (company) — Registrant
- September 2, 2025 (date) — Earliest event reported date
- November 18, 2025 (date) — Filing date of the amendment
- NuVilex, Inc. (company) — Former company name
- Nevada (location) — State of incorporation
- 3960 Howard Hughes Parkway, Suite 500 (address) — Principal Executive Offices
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing serves as an amendment to a previous report, specifically concerning financial statements and exhibits.
When was the earliest event reported in the original filing?
The earliest event reported in the original filing was on September 2, 2025.
What is PharmaCyte Biotech, Inc.'s principal executive office address?
The principal executive offices are located at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada 89169.
What was PharmaCyte Biotech, Inc. formerly known as?
PharmaCyte Biotech, Inc. was formerly known as NuVilex, Inc.
In which state is PharmaCyte Biotech, Inc. incorporated?
PharmaCyte Biotech, Inc. is incorporated in Nevada.
Filing Stats: 1,036 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2025-11-18 16:05:32
Key Financial Figures
- $0.0001 — h registered Common Stock , Par Value $0.0001 Per Share PMCB The Nasdaq Stock Ma
- $0.001 — shares of Q/C's common stock, par value $0.001 per share (the "Q/C Common Shares"), an
- $3,000,000 — rds, for an aggregate purchase price of $3,000,000 (the purchase of the Q/C Preferred Shar
Filing Documents
- pharmacyte_8ka.htm (8-K/A) — 35KB
- pharmacyte_ex2301.htm (EX-23.1) — 2KB
- pharmacyte_ex2302.htm (EX-23.2) — 2KB
- pharmacyte_ex9901.htm (EX-99.1) — 943KB
- pharmacyte_ex9902.htm (EX-99.2) — 676KB
- pharmacyte_ex9903.htm (EX-99.3) — 107KB
- 0001683168-25-008512.txt ( ) — 2115KB
- pmcb-20250902.xsd (EX-101.SCH) — 3KB
- pmcb-20250902_lab.xml (EX-101.LAB) — 33KB
- pmcb-20250902_pre.xml (EX-101.PRE) — 22KB
- pharmacyte_8ka_htm.xml (XML) — 4KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (a) Financial Statements of Business Acquired The audited consolidated financial statements of Q/C as of December 31, 2024 and 2023, and for the years ended December 31, 2024 and 2023, together with the notes thereto and reports of independent auditors thereon, are filed as Exhibit 99.1 to this Amended 8-K and are incorporated herein by reference. The unaudited condensed consolidated financial 99.2 to this Amended 8-K and are incorporated herein by reference. (b) Pro Forma Financial Information The following unaudited pro forma condensed combined financial information of the Company and Q/C, which reflect the Transaction, are filed as Exhibit 99.3 to this Amended 8-K and are incorporated herein by reference: Unaudited Pro Forma Condensed Combined Balance Sheet as of April 30, 2025; Unaudited Pro Forma Condensed Combined Unaudited Pro Forma Condensed Combined Notes to the Unaudited Pro Forma Condensed Combined Financial Information. The unaudited pro forma condensed combined financial information included in this Amended 8-K has been presented for informational and illustrative purposes only. It does not purport to represent the actual results of operations that the Company and Q/C would have achieved had the businesses been combined during the periods presented in the unaudited pro forma condensed combined financial information and is not intended to project the future results of operations that the combined businesses may achieve after the Transaction was consummated. 2 (c) Exhibits Exhibit Number Description 23.1 Consent of Stephano Slack LLC, independent auditor of Q/C . 23.2 Consent of Morison Cogen LLP, independent auditor
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 18, 2025 PHARMACYTE BIOTECH, INC. By: /s/ Carlos Trujillo Name: Carlos Trujillo Title: Chief Financial Officer 4